Literature DB >> 22513323

Lessons learned from HIV-1 vaccine trials: new priorities and directions.

Andrew J McMichael1, Barton F Haynes.   

Abstract

A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22513323      PMCID： PMC3652652          DOI： 10.1038/ni.2264

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


  63 in total

1.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors:  Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

2.  Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.

Authors:  Mattia Bonsignori; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Lynn Morris; Elin Gray; Dawn J Marshall; John A Crump; Saidi H Kapiga; Noel E Sam; Faruk Sinangil; Marie Pancera; Yang Yongping; Baoshan Zhang; Jiang Zhu; Peter D Kwong; Sijy O'Dell; John R Mascola; Lan Wu; Gary J Nabel; Sanjay Phogat; Michael S Seaman; John F Whitesides; M Anthony Moody; Garnett Kelsoe; Xinzhen Yang; Joseph Sodroski; George M Shaw; David C Montefiori; Thomas B Kepler; Georgia D Tomaras; S Munir Alam; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

3.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Authors:  Johannes F Scheid; Hugo Mouquet; Beatrix Ueberheide; Ron Diskin; Florian Klein; Thiago Y K Oliveira; John Pietzsch; David Fenyo; Alexander Abadir; Klara Velinzon; Arlene Hurley; Sunnie Myung; Farid Boulad; Pascal Poignard; Dennis R Burton; Florencia Pereyra; David D Ho; Bruce D Walker; Michael S Seaman; Pamela J Bjorkman; Brian T Chait; Michel C Nussenzweig
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

4.  Protective HIV-specific CD8+ T cells evade Treg cell suppression.

Authors:  Shokrollah Elahi; Warren L Dinges; Nicholas Lejarcegui; Kerry J Laing; Ann C Collier; David M Koelle; M Juliana McElrath; Helen Horton
Journal:  Nat Med       Date:  2011-07-17       Impact factor: 53.440

5.  The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Authors:  Elin S Gray; Maphuti C Madiga; Tandile Hermanus; Penny L Moore; Constantinos Kurt Wibmer; Nancy L Tumba; Lise Werner; Koleka Mlisana; Sengeziwe Sibeko; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

6.  Impairment of CD1d-restricted natural killer T cells in chronic HIV type 1 clade C infection.

Authors:  Marianne W Mureithi; Kristen Cohen; Ramona Moodley; Danielle Poole; Zenele Mncube; Anne Kasmar; D Branch Moody; Philip J R Goulder; Bruce D Walker; Marcus Altfeld; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-13       Impact factor: 2.205

Review 7.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Garnett Kelsoe; M Anthony Moody; Barton F Haynes
Journal:  Curr Opin Immunol       Date:  2011-04-27       Impact factor: 7.486

8.  Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.

Authors:  Ben-Jiang Ma; S Munir Alam; Eden P Go; Xiaozhi Lu; Heather Desaire; Georgia D Tomaras; Cindy Bowman; Laura L Sutherland; Richard M Scearce; Sampa Santra; Norman L Letvin; Thomas B Kepler; Hua-Xin Liao; Barton F Haynes
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

9.  Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.

Authors:  Scott G Hansen; Julia C Ford; Matthew S Lewis; Abigail B Ventura; Colette M Hughes; Lia Coyne-Johnson; Nathan Whizin; Kelli Oswald; Rebecca Shoemaker; Tonya Swanson; Alfred W Legasse; Maria J Chiuchiolo; Christopher L Parks; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Michael Piatak; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2011-05-11       Impact factor: 49.962

10.  Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes.

Authors:  Geoffrey O Gillard; Maytal Bivas-Benita; Avi-Hai Hovav; Lauren E Grandpre; Michael W Panas; Michael S Seaman; Barton F Haynes; Norman L Letvin
Journal:  PLoS Pathog       Date:  2011-08-04       Impact factor: 6.823
View more
  45 in total

1.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

3.  [HIV 2012 : research update].

Authors:  G M N Behrens
Journal:  Internist (Berl)       Date:  2012-10       Impact factor: 0.743

4.  CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.

Authors:  Zenaido T Camacho; Mallory A Turner; Michael A Barry; Eric A Weaver
Journal:  Hum Gene Ther       Date:  2014-04-10       Impact factor: 5.695

5.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

6.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

7.  HIV vaccines: can CD4+ T cells be of help?

Authors:  Eva Van Braeckel; Geert Leroux-Roels
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

8.  Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.

Authors:  Beatrice Ondondo; Hayato Murakoshi; Genevieve Clutton; Sultan Abdul-Jawad; Edmund G-T Wee; Hiroyuki Gatanaga; Shinichi Oka; Andrew J McMichael; Masafumi Takiguchi; Bette Korber; Tomáš Hanke
Journal:  Mol Ther       Date:  2016-01-08       Impact factor: 11.454

9.  HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Authors:  Mangala Rao; Kristina K Peachman; Jiae Kim; Guofen Gao; Carl R Alving; Nelson L Michael; Venigalla B Rao
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

Review 10.  CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis.

Authors:  Korey R Demers; Morgan A Reuter; Michael R Betts
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.